General Hematology
Consensus Paper: Diagnosis and treat-to-target management of macrophage activation syndrome in children.
24 Jun, 2022 | 11:13h | UTC
M-A: Intravenous iron vs. oral iron vs. no iron with or without erythropoiesis‐ stimulating agents for cancer patients with anemia.
23 Jun, 2022 | 10:10h | UTC
Analysis of thromboembolic and thrombocytopenic events after the AstraZeneca, Pfizer, and Moderna COVID-19 vaccines in 3 Nordic countries.
15 Jun, 2022 | 11:17h | UTC
Cohort Study: Mortality among patients undergoing blood transfusion in relation to donor sex and parity.
14 Jun, 2022 | 10:56h | UTCNews Release: Red blood cell units from female blood donors do not increase risk of death of transfused patients – Karolinska Institutet
BSH guideline for the hematological management of major hemorrhage.
13 Jun, 2022 | 10:53h | UTC
Systematic Review: Evidence-based perioperative diagnosis and management of pulmonary embolism.
9 Jun, 2022 | 10:34h | UTC
Brief Review: Management of antiplatelet therapy in patients with coronary stents undergoing noncardiac surgery.
6 Jun, 2022 | 10:55h | UTC
BSH Guidelines for thrombophilia testing.
2 Jun, 2022 | 11:28h | UTCGuidelines for thrombophilia testing: A British Society for Haematology guideline
NIH Updated Guideline: Antithrombotic therapy in patients with COVID-19.
2 Jun, 2022 | 11:25h | UTCAntithrombotic Therapy in Patients With COVID-19 – National Institutes of Health
BIOIRON Society recommends new classification of hemochromatosis.
24 May, 2022 | 08:09h | UTCNews Release: BIOIRON Society Recommends New Classification of Hemochromatosis – ASH Clinical News
See Guidance: Hemochromatosis classification: update and recommendations by the BIOIRON Society – Blood
Review: Role of direct oral anticoagulants for post-operative venous thromboembolism prophylaxis.
18 May, 2022 | 10:46h | UTC
Commentary on Twitter
Our work on this review summarises the pharmacological profile of DOACs and highlights the use of #DOACs in post-operative #VTE prophylaxis based on the available clinical trialhttps://t.co/7MRvWBfaEG @radcliffeCARDIO @mmamas1973 @AnastasiaSMihai @mirvatalasnag @KardiologieHH pic.twitter.com/MW6n2CWGe0
— Henry Han, MBBS, MD (@HanCardiomd) May 13, 2022
Under a CC-BY-NC 4.0 license
Guideline Synopsis: Antithrombotic therapy for venous thromboembolism.
17 May, 2022 | 11:12h | UTCAntithrombotic Therapy for Venous Thromboembolism – JAMA (free for a limited period)
Original Guideline: Antithrombotic Therapy for VTE Disease
Second Update of the CHEST Guideline and Expert Panel Report
Cohort Study: Venous or arterial thrombosis and deaths among COVID-19 cases.
17 May, 2022 | 11:02h | UTCInvited Commentary: Risk of arterial and venous thromboses after COVID-19 – The Lancet Infectious Diseases
News Release: COVID-19’s high blood clot risk – University of Oxford
Commentary on Twitter
Clots with Covid: Multi-national report of over 900,000 people indicates propensity of risk for arterial and venous thrombi is in men, with increasing age, and association with fatalities (4-fold in non-hospitalized) https://t.co/muGnDld4Um pic.twitter.com/6bLiHPLInm
— Eric Topol (@EricTopol) May 13, 2022
Under a Creative Commons Attribution (CC BY 4.0) license
Cohort Study: Sustainability of a clinical decision support intervention for outpatient care for emergency department patients with acute pulmonary embolism.
17 May, 2022 | 10:44h | UTCRelated: Outpatient versus inpatient treatment for acute pulmonary embolism – Cochrane Library
Commentary on Twitter
This multicenter cohort study of ED patients with acute pulmonary embolism found the initial increase in outpatient management from a physician champion-led, EHR-embedded clinical decision support intervention was sustained 4 years later. https://t.co/UPf8pAOTry
— JAMA Network Open (@JAMANetworkOpen) May 16, 2022
M-A: Direct oral anticoagulants not as effective as vitamin K antagonists in patients with antiphospholipid syndrome.
13 May, 2022 | 10:43h | UTC
Review: Hemophagocytic Lymphohistiocytosis in patients with HIV.
11 May, 2022 | 10:47h | UTCA Review of Hemophagocytic Lymphohistiocytosis in Patients With HIV – Open Forum Infectious Diseases
Point/Counterpoint: Should therapeutic heparin be administered to acutely ill hospitalized patients with COVID-19?
3 May, 2022 | 11:04h | UTCCOUNTERPOINT: Should Therapeutic Heparin Be Administered to Acutely Ill Hospitalized Patients With COVID-19? No – CHEST
See also: Rebuttal From Dr Tritschler et al – CHEST
Related:
Anticoagulants for people hospitalised with COVID‐19 – Cochrane Library
National, regional, and global estimates of anemia by severity in women and children for 2000–19.
20 Apr, 2022 | 09:25h | UTCInvited Commentary: Sustainable Development Goals for anaemia: 20 years later, where are we now? – The Lancet Global Health
Phase 1–2 clinical trial: Rilzabrutinib, an oral BTK inhibitor, in immune thrombocytopenia.
19 Apr, 2022 | 01:35h | UTCRilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Rilzabrutinib for blood disorder shows promise in phase 1–2 clinical trial – Massachusetts General Hospital
Commentary on Twitter
Rilzabrutinib had rapid and durable clinical activity in adults with immune thrombocytopenia, with low-level toxic effects. https://t.co/boWT4LpQkk pic.twitter.com/ZpNXHYL2Gv
— NEJM (@NEJM) April 18, 2022
RCT: Mitapivat vs. placebo for Pyruvate Kinase Deficiency.
18 Apr, 2022 | 10:13h | UTCMitapivat versus Placebo for Pyruvate Kinase Deficiency – New England Journal of Medicine
Cohort Study: Non-O blood type is associated with increased risk of venous thromboembolism in patients with cancer.
14 Apr, 2022 | 08:29h | UTCABO blood group type and risk of venous thromboembolism in patients with cancer – Blood Advances (link to abstract – $ for full-text)
Review: Cutaneous manifestations of monoclonal gammopathy.
14 Apr, 2022 | 08:21h | UTCCutaneous manifestations of monoclonal gammopathy – Blood Cancer Journal
M-A: Thrombosis patterns and clinical outcome of COVID-19 vaccine-induced immune thrombotic thrombocytopenia.
8 Apr, 2022 | 10:50h | UTCRelated:
Case series of Thrombosis with Thrombocytopenia Syndrome after Covid-19 vaccination in the US.
Review: Vaccine-induced immune thrombotic thrombocytopenia.
Vaccine induced immune thrombocytopenia and thrombosis: summary of NICE guidance.
Clinical features of vaccine-induced immune thrombocytopenia and thrombosis.
Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know.
Very rare cases of thrombosis with thrombocytopenia syndrome (TTS) after AstraZeneca vaccine: a global safety database analysis – the estimated rate of TTS after the first dose was 8.1 per million vaccinees; after the second dose, the estimated rate was 2.3 per million vaccinees. (several articles and resources on the subject)
Study finds increased risk of pulmonary embolism up to 110 days after COVID-19.
7 Apr, 2022 | 10:06h | UTCNews Release: Study finds increased risk of serious blood clots up to six months after COVID-19 – BMJ
Editorial: Thromboembolism and bleeding after covid-19
Commentary: Covid: Blood clot risk higher for six months after having virus – BBC
M-A: Risk of recurrence in women with venous thromboembolism related to estrogen-containing contraceptives.
6 Apr, 2022 | 10:55h | UTC